Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.

​Note: Phase 1, 2 and 3 studies evaluate the safety and efficacy of a medication, device, or procedure for the treatment of a medical condition.  Phase 4 studies further evaluate a drug or device that has already been FDA-approved.  Studies with no phase specified can include evaluations of exercise, physical therapy, speech therapy, dietary supplements, devices & more.​

Parkinson's Disease interventional studies

      CLINICAL TRIALS BY PHASE

​Note: 667 total active trials includes 408 recruiting, 117 not yet recruiting, 33 enrolling by invitation and 109 no longer recruiting.

An INTERVENTIONAL STUDY (or Clinical Trial) is a clinical study in which participants are assigned an intervention such as a medication, device, or procedure, so that researchers can evaluate its effects on biomedical or health-related outcomes.  Participants may receive diagnostic, therapeutic, or other types of interventions. (ClinicalTrials.gov Glossary Terms)


As of January 31, 2024, there are 667 active interventional studies for Parkinson's disease, of which 179 are in Phases 1-3.


​​​Reporting requirements for clinical trials registered on ClinicalTrials.gov

2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements
2008: ClinicalTrials.gov Releases Results Database

​2016: Final Rule for Clinical Trials Registration and Results Information Submission (Final Rule for FDAAA 801)


Reported results for completed Phase 1-3 PD trials with "primary completion date" after 1/1/17

COMPLETED CLINICAL TRIALS

... and click on country/state to view trial listings.

​​PDTrialTracker.info

707 completed Phase 1-3 PD trials (as of January 25, 2023)

To view publications of completed studies, you can search PubMed to find publication abstracts and authors, as well as links to full publications. Helpful keywords to use in a search are trial name, trial NCT# (i.e., ClinicalTrials.gov trial ID), principal investigator name, and sponsor name.  PubMed is a free resource developed by the National Center for Biotechnology Information (NCBI) at the U.S. NIH.    

83 terminated Phase 1-3 PD trials (as of January 25, 2023)